BMCS Hot Topics: PROTACs and Glues 2025
Event
BMCS Hot Topics: PROTACs and Glues
Dates
Wednesday 28 May 2025 (afternoon) 12:30 – 17:00 UK Time
Place
Online event, Zoom
Important links and downloads
X Hashtag – #HotTopicsPAG25
Synopsis
The BMCS Hot Topics online meetings are intended to highlight breaking areas of research in fields of science relevant to drug discovery. They will run as stand-alone half-day virtual events, 2-3 times per year. The programme will be targeted towards researchers working who would like to enhance their understanding of these nascent or developing fields.
While conventional small molecule drugs typically inhibit or activate proteins, PROTACs and glues offer new strategies to modulate biological pathways by either removing proteins entirely or enhancing their interactions to elicit a pharmacological effect. This meeting will feature presentations on the application and development of PROTACs, glues, and bifunctional molecules in chemical biology and drug discovery, highlighting their roles in both protein degradation and the modulation of new and existing protein-protein interactions (PPIs).
Registration
Please click here to register.
Registration Fees
RSC Member: £50.00
Non-Member: £75.00
RSC Student Member (undergraduate or post graduate): £35.00
Student Non-Member (undergraduate or post graduate): £50.00
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Sponsorship
The organising committee are seeking sponsorship from organisations supporting the low registration fees offered to students. Please click here to register as a sponsor.
Sponsors
Programme (Please note the times are in UK time)
| 12:30 | Opening Remarks |
|---|---|
| Session Chair: Ian Churcher, Janus Drug Discovery | |
| 12:35 | Protein degraders: New insights and twists of molecular mechanism and drug design Prof Alessio Ciulli, University of Dundee, UK |
| 13:15 | Gwenn Hansen, Nurix Therapeutics, USA |
| 13:45 | Dr Andrea Testa, Trimtech, UK |
| 14:15 | Break |
| Session Chair: Ian Churcher, Janus Drug Discovery | |
| 14:30 | Discovery of an oral ERα PROTAC with extended efficacy Dr Thomas Hayhow, AstraZeneca, UK |
| 15:00 | LingLing Shen, Novartis, USA |
| 15:30 | Break |
| Session Chair: Helen Aylott, Redx Pharma | |
| 15:45 | Kyle Eastman, Halda Therapeutics, USA |
| 16:15 | Towards new cancer medicines with degraders of chromatin regulatory proteins Danette Daniels, Foghorn Therapeutics, USA |
| 16:45 | Closing Remarks |
| 16:50 | Close |
Organising Committee
Adrian Hall, UCB
Daniel O Donovan, AstraZeneca
Helen Aylott, Redx Pharma
Chris Swain, Cambridge MedChem Consulting
Ian Churcher, Janus Drug Discovery
Secretariat Contact
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail
